Altruist Biologics Congratulates Partner LongBio Pharma on the BLA Acceptance of LP-003 by the China NMPA

China's NMPA accepted LongBio Pharma's BLA for LP-003, a next-generation anti-IgE monoclonal antibody for seasonal allergic rhinitis and the first such candidate to reach BLA filing in China. The drug addresses a potential market of more than 200 million Chinese allergic-rhinitis patients, where anti-IgE therapies have not previously been approved. The milestone advances LP-003 toward commercialization and validates Altruist Biologics' end-to-end CMC, GMP manufacturing and regulatory-support platform.

Analysis

For 1779.HK, the filing milestone modestly de-risks the lead asset but does not yet establish commercial value. The key valuation swing factors over the next 6-12 months are review timing, label breadth, reimbursement positioning and whether LP-003 can show a clinically meaningful dosing, efficacy or safety advantage versus established anti-IgE benchmarks; without differentiation, China biologics pricing pressure could sharply limit peak-sales assumptions. The addressable patient population is not a usable revenue proxy because severe, specialist-treated patients and out-of-pocket affordability will determine penetration.

For 1801.HK, this is stronger as a reference account than as a near-term earnings catalyst. External CDMO utilization can improve fixed-cost absorption at Altruist's manufacturing network, but consolidated revenue recognition, transfer-pricing treatment and client concentration are required before attributing material EBITDA upside to this program. The more important second-order implication is that a clean approval and commercial batch ramp would validate Altruist's ability to retain clients from development through supply, improving its competitive position against China CDMO peers such as Wuxi Biologics (2269.HK) in an environment where customers increasingly value regulatory-ready domestic capacity.

Consensus may overvalue BLA acceptance as a binary approval signal. A delayed review, manufacturing-information request, restrictive label, or delayed payer access would leave LongBio carrying launch-readiness costs without revenue; conversely, approval alone could be underappreciated if management demonstrates cross-indication leverage in allergy and builds a credible commercial channel. The immediate signal is therefore insufficient for a directional position absent data on expected review date, launch price, gross margin, capacity reservation and launch investment.

Key Decisions for Investors

• Maintain 1779.HK as a catalyst watch rather than initiate at filing acceptance. Reassess on disclosed review timeline and proposed pricing; initiate only if approval visibility improves while implied LP-003 value remains below a probability-weighted China launch case. Falsifier: a material delay, CMC query, or guidance indicating elevated pre-launch cash burn.
• Add 1801.HK to a 6-18 month watchlist for CDMO utilization upside, but do not capitalize this contract without disclosed third-party manufacturing revenue or capacity-utilization data. A commercial supply agreement with visible minimum volumes would be the actionable trigger; risk is that incremental batches merely displace higher-margin internal capacity.
• For investors seeking China biologics exposure, prefer a small relative-value framework of long 1801.HK versus short 2269.HK only after evidence that Altruist is winning external commercial programs and the utilization gap is narrowing. Exit if 1801.HK fails to disclose external CDMO growth over the next two reporting periods or if 2269.HK reaccelerates order growth.
• Set alerts for NMPA approval, reimbursement/list-price disclosure, and any LP-003 cross-indication clinical update. These events—not the accepted filing—are the points most likely to alter 1779.HK revenue estimates and 1801.HK manufacturing-demand assumptions.